Mesoblast is steadily advancing its pipeline, presenting positive Phase II data at the American Diabetes Association in June for MPC-300-IV in moderate-to-severe diabetic nephropathy. The company is seeking an accelerated regulatory path on findings in a large patient population with little alternative for treatment. The recent agreement with Celgene, which entailed a net A$58.5m equity purchase in return for first right of refusal on products in certain disease areas, provides Mesoblast with
23 Jul 2015
Headway on positive developments
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Headway on positive developments
Mesoblast is steadily advancing its pipeline, presenting positive Phase II data at the American Diabetes Association in June for MPC-300-IV in moderate-to-severe diabetic nephropathy. The company is seeking an accelerated regulatory path on findings in a large patient population with little alternative for treatment. The recent agreement with Celgene, which entailed a net A$58.5m equity purchase in return for first right of refusal on products in certain disease areas, provides Mesoblast with